Ribupatide
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
Fujian Shengdi Pharmaceutical Co · Phase 3 · Recruiting · Enrollment 675
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| HRS9531 Tablet Group | Obesity or overweight | n/r | n/r | n/r | n/r |
| HRS9531 Tablet Placebo Group | Obesity or overweight | n/r | n/r | n/r | n/r |